← Eichor
Study identifier: NCT06806345 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Hyperbaric Oxygen Therapy on Insulin Resistance in Postmenopause

Condition: Insulin Resistance Syndrome  ·  Sponsor: Cairo University

PhasePhase 1/Phase 2
Planned participants40
Who can joinFemale, 55 Years to 65 Years
Healthy volunteersNo

About this study

Background: In postmenopausal females, Insulin resistance is commonly encountered in clinical setting. Hyperbaric oxygen therapy have been proposed effective in lowering blood glucose level and improving function. Identification of clinical examination variables as predictors to blood glucose levels and dysfunction would offer therapists the chance to undertake clinical decisions and consequently improve treatment efficiency. Objectives: This Predictive validity, diagnostic study conduct to examine the effect of hyperbaric oxygen therapy on insulin resistance in postmenopausal women.

This description comes directly from the study's public registry record.

Talk to the study team

Siham mohamed fahmy Head of Hyperbaric oxygen therapy unit, Assistant professor  ·  01033380185  ·  Fahmysiham@gmail.com

Kobry el koba military complex Kobry el koba military complex, Military Medical complex  ·  0222638885  ·  info@KobryKobba.com.eg

Always discuss trial participation with your own doctor first.

Locations (1)

Kobry el koba military complexCairo, Cairo Governorate, EgyptRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06806345